Figure 5

Direct suppression of RBM47 by IL-6 activated STAT3. (a and b) Expression of RBM47 mRNA in (a) DLD1 or (b) HT29 CRC cells after treatment with IL-6 (20 ng/ml) or vehicle for 72 hours. (c) Western blot analysis of indicated proteins in DLD1 cells after exposure to IL-6 (20 ng/ml) for the indicated periods. (d) Map of the human RBM47 promoter region with the indicated conserved STAT3 and SNAIL binding sites. Filled rectangles represent the binding sites. TF binding sequence motifs are indicated by grey shadowing. Their conservation between species is indicated by asterisks. The arrow indicates the TSS, // represent additional, not shown sequences between the BDS. (e) qChIP analysis of STAT3 occupancy at the RBM47 promoter and, as a control, the acetylcholine receptor (ACHR) locus in DLD1 cells treated with vehicle or IL-6 for 20 minutes. In a,b, and e mean values ± SD (n = 3) are provided with *P < 0.05; **P < 0.01; ***P < 0.001.